600276 Stock Overview
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 600276 from our risk checks.
Jiangsu Hengrui Medicine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥42.35 |
| 52 Week High | CN¥50.50 |
| 52 Week Low | CN¥35.51 |
| Beta | 0.22 |
| 1 Month Change | -7.87% |
| 3 Month Change | 2.27% |
| 1 Year Change | -11.40% |
| 3 Year Change | -38.18% |
| 5 Year Change | -4.56% |
| Change since IPO | 7,084.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600276 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.8% | -0.7% | -0.2% |
| 1Y | -11.4% | -15.9% | -17.8% |
Return vs Industry: 600276 exceeded the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 600276 exceeded the CN Market which returned -17.8% over the past year.
Price Volatility
| 600276 volatility | |
|---|---|
| 600276 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 600276 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600276's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | 19,611 | Hong Bin Dai | www.hrs.com.cn |
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications.
Jiangsu Hengrui Medicine Co., Ltd. Fundamentals Summary
| 600276 fundamental statistics | |
|---|---|
| Market cap | CN¥269.29b |
| Earnings (TTM) | CN¥4.43b |
| Revenue (TTM) | CN¥23.32b |
60.8x
P/E Ratio11.5x
P/S RatioIs 600276 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600276 income statement (TTM) | |
|---|---|
| Revenue | CN¥23.32b |
| Cost of Revenue | CN¥3.65b |
| Gross Profit | CN¥19.68b |
| Other Expenses | CN¥15.25b |
| Earnings | CN¥4.43b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 84.37% |
| Net Profit Margin | 19.00% |
| Debt/Equity Ratio | 0% |
How did 600276 perform over the long term?
See historical performance and comparison